EMA Authorised: Ezmekly (mirdametinib) — SpringWorks Therapeutics Ireland Limited

View source ↗

Summary

The European Medicines Agency authorised Ezmekly (mirdametinib) for neurofibromatosis type 1 with plexiform neurofibromas, under conditional approval and orphan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Ezmekly (mirdametinib)

Snippet

Status: Authorised. Therapeutic area: Neurofibromatosis 1;Neurofibroma, Plexiform. MAH: SpringWorks Therapeutics Ireland Limited. Decision date: 12/03/2026. Conditional approval. Orphan medicine